China Economic Net, Beijing, May 10 (Reporter Wang Wanying) Zhou Jian, deputy director of the Consumer Goods Industry Department of the Ministry of Industry and Information Technology, said today that it is necessary to strengthen the layout of the frontier and original innovation fields of the pharmaceutical industry, from "following" innovation to "leading" "Innovative progress, promote the research and development and industrialization of a number of new drugs and new medical devices, and strive to achieve "parallel running" or even "leading" in some fields.

  The biopharmaceutical industry is an important part of the bioeconomy, a strategic emerging industry related to the national economy and people's livelihood and national security, and an important foundation for the construction of a healthy China.

  In recent years, the biopharmaceutical industry has developed vigorously. "Faced with the sudden new crown pneumonia epidemic, the complete industrial chain and strong supply capacity of my country's biopharmaceutical industry not only withstood the test of the epidemic, but also because of its complete industrial system advantages and strong mobilization. Organizational ability and resilience have made important contributions to epidemic prevention and control and the realization of stable economic development." Zhou Jian said.

  In order to speed up the construction of a modern bio-industry system, promote the protection and utilization of biological resources in an orderly manner, and focus on making the bio-economy bigger and stronger, the National Development and Reform Commission has issued the "14th Five-Year Plan" for Bio-economy Development.

  The "Planning" proposes to develop biomedicine oriented to people's life and health to meet the people's new expectations for more protection of life and health.

To this end, the Ministry of Industry and Information Technology will work with relevant departments to comprehensively improve the modernization level of the pharmaceutical industry based on the new development stage.

  One is to accelerate the development of cutting-edge technologies.

Grasp the new trend of accelerated iteration of global biotechnology, strengthen the layout of frontier and original innovation fields, move from "following" innovation to "leading" innovation, and encourage the deep integration of industry, academia, research and medicine.

Adhere to open cooperation, promote open innovation and development, and create a modern innovation ecosystem of biomedical manufacturing that deeply integrates industrial chain, innovation chain, value chain, and supply chain.

  The second is to strengthen the core technology research.

Zhou Jian revealed that the Ministry of Industry and Information Technology will focus on the weak links in the industrial chain and supply chain to carry out key technical research to make up for shortcomings; further develop and apply advanced manufacturing technologies and equipment, enhance key core competitiveness, improve total factor production efficiency, and continuously strengthen scale and system. Chemical manufacturing advantages; promote the high-end, intelligent and green development of the pharmaceutical industry.

  The third is to improve the innovation service system.

Support pharmaceutical enterprises to strengthen cooperation with national laboratories, scientific research institutions, high-level research universities and other institutions, jointly build a national strategic scientific and technological force in the field of biomedicine, and promote the orderly connection and joint development of the transformation of achievements.

  The fourth is to enhance the competitiveness of pharmaceutical enterprises.

Implement the cultivation project of pharmaceutical pilot enterprises, and combine with the implementation of policies such as consistency evaluation of generic drugs and procurement with volume, support large-scale enterprises to implement innovation and transformation, improve market competitiveness and sustainable development capabilities, and form a group of highly internationalized, global layout development of large pharmaceutical companies.

Cultivate emerging forces for industrial development, and support the development of specialized, specialized, and new "little giants" that focus on subdivisions, have high levels of specialization, and have strong innovation capabilities.

Give full play to the advantages of small and medium-sized enterprises with strong innovation vitality and sound industrialization system of large-scale enterprises, promote large- and medium-sized enterprises to strengthen cooperation in product, technology, market, capital and other aspects, and promote the formation of an industrial ecology of coordinated development of large and medium-sized enterprises.